Solcitinib
A potent, selective JAK1 inhibitor for the treatment of psoriasis, lupus, and ulcerative colitis.Psoriasis Phase 2 Clinical (In Vitro) :Solcitinib is an orally active, competitive, potent, selective JAK1 inhibitor, with an IC50 of 9.8 nM, and 11-, 55- and 23-fold selectivity over JAK2, JAK3 and TYK2, respectively. Solcitinib is used in the research of moderate-to-severe plaque-type psoriasis.
Product Specifications
CAS Number
1206163-45-2
Product Name Alternative
GSK-2586184 | GLPG-0778
Purity
>98% (HPLC)
Solubility
DMSO: 20 mg/mL
Smiles
CC1 (CN (C1) C (=O) C2=CC=C (C=C2) C3=CC=CC4=NC (=NN43) NC (=O) C5CC5) C
Molecular Formula
C22H23N5O2
Molecular Weight
389.4503
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
Cyclopropanecarboxamide, N-[5-[4-[ (3,3-dimethyl-1-azetidinyl) carbonyl]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl]-
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Tmem70 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 3)
Recombinant Arabidopsis thaliana Putative cyclic nucleotide-gated ion channel 13 (CNGC13)